Real-world 6 and 12-month Drug Retention, Remission and Response Rates of Secukinumab in 2,017 Psoriatic Arthritis patients in 13 European Countries
Citation
Michelsen , B , Georgiadis , S , Di Giuseppe , D , Loft , A G , Nissen , M J , Iannone , F , Pombo-Suarez , M , Mann , H , Rotar , Z , Eklund , K K , Kvien , T K , Santos , M J , Gudbjornsson , B , Codreanu , C , Yilmaz , S , Wallman , J K , Brahe , C H , Möller , B , Favalli , E G , Sánchez-Piedra , C , Nekvindova , L , Tomsic , M , Trokovic , N , Kristianslund , E K , Santos , H , Löve , T J , Ionescu , R , Pehlivan , Y , Jones , G T , van der Horst-Bruinsma , I , Ørnbjerg , L M , Østergaard , M & Hetland , M L 2022 , ' Real-world 6 and 12-month Drug Retention, Remission and Response Rates of Secukinumab in 2,017 Psoriatic Arthritis patients in 13 European Countries ' , Arthritis Care & Research , vol. 74 , no. 7 , pp. 1205-1218 . https://doi.org/10.1002/acr.24560
Rights
© 2021 The Authors. Arthritis Care & Research published by Wiley Periodicals LLC on behalf of American College of Rheumatology. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.